Insider Transactions in Q4 2020 at Blueprint Medicines Corp (BPMC)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 24
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,455
-60.5%
|
$681,875
$125.0 P/Share
|
|
Dec 24
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,455
+37.69%
|
$152,740
$28.15 P/Share
|
|
Dec 18
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,454
-60.49%
|
$654,480
$120.0 P/Share
|
|
Dec 18
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,454
+37.69%
|
$152,712
$28.15 P/Share
|
|
Dec 17
2020
|
Charles A Rowland Jr Director |
SELL
Open market or private sale
|
Direct |
10,909
-75.39%
|
$1,276,353
$117.82 P/Share
|
|
Dec 17
2020
|
Charles A Rowland Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,909
+42.98%
|
$207,271
$19.53 P/Share
|
|
Dec 14
2020
|
Marion Dorsch Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,600
-23.17%
|
$547,400
$119.0 P/Share
|
|
Dec 14
2020
|
Marion Dorsch Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+18.81%
|
$170,200
$37.11 P/Share
|
|
Dec 14
2020
|
Anthony L. Boral Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.25%
|
$1,170,000
$117.8 P/Share
|
|
Dec 14
2020
|
Anthony L. Boral Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.77%
|
$150,000
$15.01 P/Share
|
|
Dec 14
2020
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-3.41%
|
$595,000
$119.18 P/Share
|
|
Dec 14
2020
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.3%
|
$40,000
$8.8 P/Share
|
|
Dec 11
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,455
-60.5%
|
$627,325
$115.0 P/Share
|
|
Dec 11
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,455
+37.69%
|
$152,740
$28.15 P/Share
|
|
Dec 01
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,038
-4.82%
|
$113,142
$109.54 P/Share
|
|
Dec 01
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+7.64%
|
$7,200
$8.8 P/Share
|
|
Dec 01
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,454
-60.49%
|
$599,940
$110.0 P/Share
|
|
Dec 01
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,454
+37.69%
|
$152,712
$28.15 P/Share
|
|
Nov 16
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,700
-14.55%
|
$170,000
$100.92 P/Share
|
|
Nov 16
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+6.77%
|
$8,500
$5.34 P/Share
|
|
Nov 16
2020
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
20,000
-3.25%
|
$1,960,000
$98.85 P/Share
|
|
Nov 16
2020
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+11.02%
|
$160,000
$8.8 P/Share
|
|
Nov 16
2020
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
409
-0.95%
|
$40,900
$100.27 P/Share
|
|
Nov 16
2020
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
409
+0.94%
|
$14,724
$36.05 P/Share
|
|
Nov 03
2020
|
Christina Rossi CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
345
-1.69%
|
$34,155
$99.69 P/Share
|
|
Nov 03
2020
|
Charles A Rowland Jr Director |
SELL
Open market or private sale
|
Direct |
5,522
-23.34%
|
$541,156
$98.52 P/Share
|
|
Nov 03
2020
|
Charles A Rowland Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,522
+37.81%
|
$49,698
$9.46 P/Share
|
|
Nov 02
2020
|
Charles A Rowland Jr Director |
SELL
Open market or private sale
|
Direct |
4,478
-55.7%
|
$443,322
$99.11 P/Share
|
|
Nov 02
2020
|
Charles A Rowland Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,478
+35.77%
|
$40,302
$9.46 P/Share
|
|
Oct 23
2020
|
Anthony L. Boral Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,183
+14.86%
|
$101,013
$11.91 P/Share
|
|
Oct 19
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,455
-60.5%
|
$572,775
$105.0 P/Share
|
|
Oct 19
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,455
+37.69%
|
$103,645
$19.53 P/Share
|
|
Oct 16
2020
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
13,334
-8.54%
|
$1,346,734
$101.55 P/Share
|
|
Oct 16
2020
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
13,334
+19.18%
|
$480,024
$36.05 P/Share
|
|
Oct 07
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,454
-60.49%
|
$545,400
$100.0 P/Share
|
|
Oct 07
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,454
+37.69%
|
$103,626
$19.53 P/Share
|
|
Oct 07
2020
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-3.41%
|
$495,000
$99.17 P/Share
|
|
Oct 07
2020
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.3%
|
$40,000
$8.8 P/Share
|
|
Oct 07
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
600
-5.67%
|
$60,000
$100.0 P/Share
|
|
Oct 07
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+5.36%
|
$4,800
$8.8 P/Share
|
|
Oct 06
2020
|
Marion Dorsch Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,600
-23.17%
|
$455,400
$99.0 P/Share
|
|
Oct 06
2020
|
Marion Dorsch Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+18.81%
|
$170,200
$37.11 P/Share
|
|
Oct 01
2020
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+50.0%
|
-
|
|
Oct 01
2020
|
Nicholas Lydon |
SELL
Open market or private sale
|
Direct |
9,815
-7.43%
|
$902,980
$92.87 P/Share
|